09:37 AM EDT, 08/15/2024 (MT Newswires) -- (Updates with details throughout.)

The Centers for Medicare & Medicaid Services released prices Thursday for the first 10 prescription drugs under Medicare Part D that were subject to negotiations between drugmakers and Medicare.

The negotiated prices will go into effect in 2026 and are expected to save Medicare enrollees about $1.5 billion, according to CMS. Medicare Part D is an optional prescription drug benefit for people with Medicare.

The negotiated prices compared with the 2023 list prices for the 10 drugs are as follows: Merck's ( MRK ) Januvia: $113 vs. $527; Novo Nordisk's ( NVO ) Fiasp and NovoLog: $119 vs. $495; AstraZeneca's ( AZN ) Farxiga: $178.50 vs. $556; Amgen's ( AMGN ) Enbrel: $2,355 vs. $7,106; Boehringer Ingelheim's Jardiance: $197 vs. $573; Johnson & Johnson's ( JNJ ) Stelara: $4,695 vs. $13,836; Johnson & Johnson's ( JNJ ) Xarelto: $197 vs $517; Bristol Myers Squibb's ( BMY ) Eliquis: $231 vs. $521; Novartis' ( NVS ) Entresto: $295 vs. $628; and AbbVie's ( ABBV ) Imbruvica: $9,319 vs. $14,934.

In 2023, approximately 8.8 million of the 54 million people with Medicare Part D coverage were provided with these drugs, which accounted for about 20% of total Part D gross covered prescription drug costs during the year, the CMS said.

Price: 157.75, Change: -0.73, Percent Change: -0.46